Discovery of Potent and Selective BRD4 Inhibitors Capable of Blocking TLR3-induced Acute Airway Inflammation

Overview

Journal Eur J Med Chem

Specialty Chemistry

Date 2018 Apr 13

PMID 29649741

Citations 36

Authors

Zhiqing Liu

Bing Tian

Haiying Chen

Pingyuan Wang

Allan R Brasier

Jia Zhou

Affiliations

Soon will be listed here.

Abstract

A series of diverse small molecules have been designed and synthesized through structure-based drug design by taking advantage of fragment merging and elaboration approaches. Compounds ZL0420 (28) and ZL0454 (35) were identified as potent and selective BRD4 inhibitors with nanomolar binding affinities to bromodomains (BDs) of BRD4. Both of them can be well docked into the acetyl-lysine (KAc) binding pocket of BRD4, forming key interactions including the critical hydrogen bonds with Asn140 directly and Tyr97 indirectly via a HO molecule. Both compounds 28 and 35 exhibited submicromolar potency of inhibiting the TLR3-dependent innate immune gene program, including ISG54, ISG56, IL-8, and Groβ genes in cultured human small airway epithelial cells (hSAECs). More importantly, they also demonstrated potent efficacy reducing airway inflammation in a mouse model with low toxicity, indicating a proof of concept that BRD4 inhibitors may offer the therapeutic potential to block the viral-induced airway inflammation.

Citing Articles

An updated patent review of BRD4 degraders.

Ma Z, Zhang C, Bolinger A, Zhou J Expert Opin Ther Pat. 2024; 34(10):929-951.

PMID: 39219068 PMC: 11427152. DOI: 10.1080/13543776.2024.2400166.

Cooperative interaction of interferon regulatory factor -1 and bromodomain-containing protein 4 on RNA polymerase activation for intrinsic innate immunity.

Xu X, Qiao D, Brasier A Front Immunol. 2024; 15:1366235.

PMID: 38601157 PMC: 11004252. DOI: 10.3389/fimmu.2024.1366235.

BRD4 as a Therapeutic Target in Pulmonary Diseases.

Guo X, Olajuyin A, Tucker T, Idell S, Qian G Int J Mol Sci. 2023; 24(17).

PMID: 37686037 PMC: 10487829. DOI: 10.3390/ijms241713231.

Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2).

Ma Z, Bolinger A, Chen H, Zhou J J Med Chem. 2023; 66(16):10991-11026.

PMID: 37578463 PMC: 11092389. DOI: 10.1021/acs.jmedchem.3c00948.

Pyronaridine as a Bromodomain-Containing Protein 4--Terminal Bromodomain (BRD4-BD1) Inhibitor: Database Mining, Molecular Docking, and Molecular Dynamics Simulation.

Ibrahim M, Abdelhamid M, Abdeljawaad K, Abdelrahman A, Mekhemer G, Sidhom P Molecules. 2023; 28(15).

PMID: 37570684 PMC: 10420099. DOI: 10.3390/molecules28155713.

References

Zhang G, Plotnikov A, Rusinova E, Shen T, Morohashi K, Joshua J . Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains. J Med Chem. 2013; 56(22):9251-64. PMC: 3894848. DOI: 10.1021/jm401334s. View

Tian B, Liu Z, Yang J, Sun H, Zhao Y, Wakamiya M . Selective Antagonists of the Bronchiolar Epithelial NF-κB-Bromodomain-Containing Protein 4 Pathway in Viral-Induced Airway Inflammation. Cell Rep. 2018; 23(4):1138-1151. PMC: 6020052. DOI: 10.1016/j.celrep.2018.03.106. View

Lucas X, Wohlwend D, Hugle M, Schmidtkunz K, Gerhardt S, Schule R . 4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. Angew Chem Int Ed Engl. 2013; 52(52):14055-9. DOI: 10.1002/anie.201307652. View

Dhalluin C, Carlson J, Zeng L, He C, Aggarwal A, Zhou M . Structure and ligand of a histone acetyltransferase bromodomain. Nature. 1999; 399(6735):491-6. DOI: 10.1038/20974. View

Chung C, Coste H, White J, Mirguet O, Wilde J, Gosmini R . Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem. 2011; 54(11):3827-38. DOI: 10.1021/jm200108t. View

Vidler L, Brown N, Knapp S, Hoelder S . Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J Med Chem. 2012; 55(17):7346-59. PMC: 3441041. DOI: 10.1021/jm300346w. View

Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith W, Fedorov O . Selective inhibition of BET bromodomains. Nature. 2010; 468(7327):1067-73. PMC: 3010259. DOI: 10.1038/nature09504. View

Tian B, Zhao Y, Sun H, Zhang Y, Yang J, Brasier A . BRD4 mediates NF-κB-dependent epithelial-mesenchymal transition and pulmonary fibrosis via transcriptional elongation. Am J Physiol Lung Cell Mol Physiol. 2016; 311(6):L1183-L1201. PMC: 5206405. DOI: 10.1152/ajplung.00224.2016. View

Raux B, Voitovich Y, Derviaux C, Lugari A, Rebuffet E, Milhas S . Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins. J Med Chem. 2016; 59(4):1634-41. DOI: 10.1021/acs.jmedchem.5b01708. View

10.

Liu Z, Wang P, Chen H, Wold E, Tian B, Brasier A . Drug Discovery Targeting Bromodomain-Containing Protein 4. J Med Chem. 2017; 60(11):4533-4558. PMC: 5464988. DOI: 10.1021/acs.jmedchem.6b01761. View

11.

Simmons K, Chopra I, Fishwick C . Structure-based discovery of antibacterial drugs. Nat Rev Microbiol. 2010; 8(7):501-10. DOI: 10.1038/nrmicro2349. View

12.

Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert J, Barsyte-Lovejoy D . Histone recognition and large-scale structural analysis of the human bromodomain family. Cell. 2012; 149(1):214-31. PMC: 3326523. DOI: 10.1016/j.cell.2012.02.013. View

13.

Bui M, Lin X, Albert D, Li L, Lam L, Faivre E . Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies. Cancer Res. 2017; 77(11):2976-2989. DOI: 10.1158/0008-5472.CAN-16-1793. View

14.

Belkina A, Denis G . BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer. 2012; 12(7):465-77. PMC: 3934568. DOI: 10.1038/nrc3256. View

15.

Gosmini R, Nguyen V, Toum J, Simon C, Brusq J, Krysa G . The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor. J Med Chem. 2014; 57(19):8111-31. DOI: 10.1021/jm5010539. View

16.

Jung M, Philpott M, Muller S, Schulze J, Badock V, Eberspacher U . Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1. J Biol Chem. 2014; 289(13):9304-19. PMC: 3979416. DOI: 10.1074/jbc.M113.523019. View

17.

Romero F, Taylor A, Crawford T, Tsui V, Cote A, Magnuson S . Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors. J Med Chem. 2015; 59(4):1271-98. DOI: 10.1021/acs.jmedchem.5b01514. View

18.

Yu W, Huang G, Zhang Y, Liu H, Dong L, Yu X . I2-mediated oxidative C-O bond formation for the synthesis of 1,3,4-oxadiazoles from aldehydes and hydrazides. J Org Chem. 2013; 78(20):10337-43. DOI: 10.1021/jo401751h. View

19.

Dawson M, Prinjha R, Dittmann A, Giotopoulos G, Bantscheff M, Chan W . Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011; 478(7370):529-33. PMC: 3679520. DOI: 10.1038/nature10509. View

20.

Tian B, Li X, Kalita M, Widen S, Yang J, Bhavnani S . Analysis of the TGFβ-induced program in primary airway epithelial cells shows essential role of NF-κB/RelA signaling network in type II epithelial mesenchymal transition. BMC Genomics. 2015; 16:529. PMC: 4506436. DOI: 10.1186/s12864-015-1707-x. View